Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Partially aligned with the label regarding liver enzyme abnormalities and recommended liver function testing; however, several specific “signs of liver injury” and monitoring purpose/algorithms are not supported by the provided prescribing information.
Category Scores
Accurate Statements
Lipitor (atorvastatin) can sometimes raise liver blood tests such as ALT and AST.
Supported by label section 5.2 (biochemical abnormalities of liver function/transaminase elevations).
Any liver-related effect of statins is considered a safety/monitoring issue rather than a protective indication.
Supported by label sections 5.2 and 17.2 (liver dysfunction/monitoring).
When taken, Lipitor works through the liver by lowering cholesterol production.
Supported by label section 12.2 (inhibition of HMG-CoA reductase and cholesterol synthesis in the liver).
Rare liver injury can occur with statins.
Supported by label sections 5.2 and 6.2 (including hepatic failure and liver enzyme abnormalities).
Clinicians generally monitor liver enzymes because rare liver injury can occur with statins.
Supported by label sections 5.2 and 17.2 (recommend liver function tests prior to and after initiation/dose increase, and periodically).
Clinicians may avoid or stop Lipitor if liver enzyme elevations are significant.
Supported by label section 5.2 (reduction of dose or withdrawal if ALT/AST >3x ULN persists).
Clinicians may avoid or stop Lipitor if there are signs of liver injury.
Supported by label section 5.2 (monitoring and recommendations with transaminase elevations/jaundice).
Signs that can indicate liver injury while taking Lipitor include jaundice (yellow eyes/skin).
Supported by label section 5.2 (one patient developed jaundice; LFT increases not associated with jaundice in other patients).
Cholesterol-lowering with Lipitor may still be important for heart risk.
Supported by label sections 1 and 1.1 (indications for reducing cardiovascular events risk).
Cholesterol-lowering with Lipitor is not the same as liver-directed treatment.
Supported by label framing of Lipitor indications for cardiovascular risk; label treats liver dysfunction as a safety/monitoring issue (sections 1 and 5.2).
Unsupported Statements
When taken, Lipitor works through the liver by increasing cholesterol clearance from the blood.
Partially supported at best by label 12.2 wording; provided support emphasizes LDL receptor uptake/catabolism rather than explicit 'increasing clearance from the blood' phrasing.
Clinicians may check baseline liver labs and monitor after starting Lipitor if liver enzymes are already high.
Label supports liver function tests prior to initiation and after initiation/dose increases, but the specific conditional phrasing 'if liver enzymes are already high' is not explicitly stated in the provided text.
Common practice is to obtain baseline liver blood tests before starting a statin.
Label recommends liver function tests prior to initiation, but does not use 'common practice' wording; only prior-to-initiation recommendation is supported.
Contradictions
Low
AI Statement
Signs that can indicate liver injury while taking Lipitor include dark urine.
Label Reference
Label section 5.2 does not mention dark urine as a listed sign.
Low
AI Statement
Signs that can indicate liver injury while taking Lipitor include right upper abdominal pain.
Label Reference
Label section 5.2 does not mention right upper abdominal pain as a listed sign.
Low
AI Statement
Signs that can indicate liver injury while taking Lipitor include persistent vomiting.
Label Reference
Label section 5.2 does not mention persistent vomiting as a listed sign.
Important Omissions
The label specifically recommends: liver function tests be performed prior to and at 12 weeks following initiation and any dose elevation, and periodically thereafter (e.g., semiannually), with monitoring until abnormalities resolve and dose reduction/withdrawal if ALT/AST >3x ULN persists.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
While label-supported liver monitoring and action thresholds are broadly reflected, the inclusion of multiple specific liver-injury 'signs' not present in the provided label could mislead safety/monitoring expectations. Several monitoring assertions are also only partially supported.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Partially Aligned
Primary Issue
Multiple specific 'signs of liver injury' (dark urine, right upper abdominal pain, persistent vomiting) and monitoring goals/algorithm language are not supported by the provided label text.
Suggested Improvement
Restrict liver-symptom examples to those explicitly described in the provided labeling (e.g., jaundice) and align monitoring language to the label’s recommended schedule (prior to, at 12 weeks after initiation and after dose increases, and periodically thereafter) and the stated action threshold (ALT/AST >3x ULN persisting).